Scancell Holdings Plc Notice of AGM
October 01 2024 - 2:00AM
RNS Regulatory News
RNS Number : 3234G
Scancell Holdings Plc
01 October 2024
1 October 2024
Scancell Holdings
plc
("Scancell" or the "Company")
Notice of Annual General
Meeting
Scancell Holdings plc (AIM: SCLP),
the developer of novel immunotherapies for the treatment of cancer,
announces that the Company's Annual Report and Accounts for the
year ended 30 April 2024 and Notice of Annual General Meeting
("AGM") will be sent to shareholders shortly.
The Annual Report and Accounts for
the year ended 30 April 2024 is available on the Company's website
at https://www.scancell.co.uk/investors/financial-info.
The AGM will be held at 3.00pm GMT
at the offices of Cooley (UK) LLP at 22 Bishopsgate, London, EC2N
4BQ on Friday 25th October 2024.
After the AGM, Scancell's senior
management team will be presenting the final results for the year
ended 30 April 2024 followed by a Q&A session, and
all shareholders are invited to attend in person.
-ENDS-
|
For
further information, please contact:
|
|
|
Scancell Holdings plc
|
+44 (0) 20 3709 5700
|
|
Professor Lindy Durrant,
CEO
Dr Jean-Michel Cosséry,
Non-Executive Chairman
|
|
|
Panmure Liberum Limited (Nominated Advisor and Joint Broker)
|
+44 (0) 20 7886 2500
|
|
Emma Earl/ Freddy Crossley/ Will
Goode/ Mark Rogers (Corporate Finance)
|
|
|
Rupert Dearden (Corporate
Broking)
|
|
|
WG
Partners LLP (Joint Broker)
|
+44 (0) 20 3705 9330
|
|
David Wilson/ Claes Spang/ Satheesh
Nadarajah/ Erland Sternby
|
|
|
ICR
Consilium
|
|
|
Mary-Jane Elliott/ Angela Gray/
Lindsey Neville
|
+44 (0) 20 37095700
scancell@consilium-comms.com
|
About Scancell
Scancell is a clinical stage
immunotherapy company that is leveraging its proprietary research,
built up over many years of studying the human adaptive immune
system, to generate novel medicines to treat significant unmet
needs in cancer. The Company is building a pipeline of innovative
products by utilising its four technology platforms:
Moditope® and ImmunoBody® for vaccines and
GlyMab® and AvidiMab® for antibodies.
Adaptive immune responses include antibodies and T cells (CD4 and
CD8), both of which can recognise damaged or infected cells. In
order to destroy such cancerous or infected cells, Scancell uses
either vaccines to induce immune responses or monoclonal antibodies
(mAbs) to redirect immune cells or drugs. The Company's approaches
are that vaccines (ImmunoBody® and Moditope®)
use unique receptors to target antigens to activated antigen
presenting cells whereas its mAb portfolio targets glycans or
sugars that are added onto proteins and / or lipids
(GlyMab®) or enhances the potency of antibodies and
their ability to directly kill tumour cells
(AvidiMab®).
Scancell is headquartered in Oxford,
United Kingdom and is listed on AIM (LSE.SCLP.L). For further
information about Scancell, please
visit: https://www.scancell.co.uk.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NOABLGDCDBXDGSG
Scancell (LSE:SCLP)
Historical Stock Chart
From Oct 2024 to Nov 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From Nov 2023 to Nov 2024
